A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients |
| |
Authors: | Satoshi Yoda Kenzo Soejima Hiroyuki Yasuda Katsuhiko Naoki Ichiro Kawada Hideo Watanabe Ichiro Nakachi Ryosuke Satomi Sohei Nakayama Sinnosuke Ikemura Hideki Terai Takashi Sato Maiko Morosawa Koichiro Asano |
| |
Affiliation: | Department of Pulmonary Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, 160-8582, Japan. |
| |
Abstract: | Background This phase I study was conducted to evaluate the feasibility and to determine the recommended doses of the combination therapy of S-1 and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC) as second-line treatment. Methods Patients with NSCLC who were previously treated with one chemotherapy regimen and had a performance status of 0 or 1 were eligible. CPT-11 was administered at 60 mg/m2 (level 1), 80 mg/m2 (level 2) on days 1 and 8, and oral S-1 was administered at 80 mg/day for body surface area (BSA) less than 1.25 m2, 100 mg/day for BSA 1.25–1.5 m2, and 120 mg/day for BSA more than 1.5 m2 on days 1–14 every 3 weeks. The dose-limiting toxicity (DLT) was defined as grade 4 leukocytopenia or neutropenia, grade ≥3 neutropenia with fever over 38°C, grade ≥3 thrombocytopenia, or grade ≥3 major nonhematological toxicities. Results Nine patients were enrolled in the study. None of 3 patients enrolled in level 1 had any DLT. Of 6 patients in level 2, 2 patients had grade 3 diarrhea and one had grade 3 interstitial pneumonia. Level 1 was declared as the recommended dose. Conclusion The feasibility of the combination therapy of S-1 and CPT-11 was shown in the second-line setting for the treatment of advanced NSCLC. The recommended dose of CPT-11 was 60 mg/m2 combined with standard dose of S-1 for phase II trials of pretreated advanced NSCLC patients. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|